Adult height lower in childhood leukemia survivors

	Tweet

Survivors of childhood acute lymphoblastic leukemia (ALL) have an increased risk of attaining a short stature as adults, regardless of the type of treatment they received for the cancer.

High doses of radiotherapy to the skull have been associated with growth deficits, the authors explain, but other therapies for ALL have not been consistently linked with growth suppression. 

To further investigate, Dr. Eric J. Chow from the University of Washington, Seattle, and colleagues compared the adult height of 2,434 survivors of pediatric ALL, diagnosed between 1970 and 1986, with that of 3,009 of their siblings to determine the risk factors associated with short stature.

All survivor treatment groups, including those treated with chemotherapy alone, had a decreased adult height and height standard deviation scores compared with their siblings, the authors report.

Among children diagnosed with ALL before puberty, the height standard deviation scores were lower on average among those exposed to any dose of craniospinal radiotherapy than those treated with cranial radiotherapy alone.

The effect of radiotherapy on adult height was not as great for children who were diagnosed after puberty, the researchers report in the Journal of Pediatrics, and the effect was not statistically different than that of chemotherapy alone.

Survivors of ALL were more than 12 times as likely as their siblings to be short, the report indicates, and the risk of adult short stature was greater for those diagnosed before puberty than for those diagnosed later.

Female survivors were more likely than male survivors to have a short stature in adulthood, even after the investigators factored in the effects of age, puberty status at diagnosis, ethnicity and radiotherapy exposures.

“As most patients with ALL are currently treated exclusively with chemotherapy,” the authors conclude, “future analyses should focus on understanding better the relationships between adult height and chemotherapy dose, duration and type.”

SOURCE: Journal of Pediatrics, April, 2007. 

RELATED STORIES:
Finding indicate why some kinds of Leukemia are more aggressive than others   Disparities among patients with extremity soft-tissue sarcomas   No link between leukemia risk and nuclear plants   Petrochemicals linked to leukemia in young adults   White Blood Cell Count, Inflammation Linked to Cancer Deaths   Researchers Seek Alternative for Leukemia Patients Resistant to Standard Therapies   ODC Therapy, Inc. Reports Melanoma Vaccine Research Results   2 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma   Immunotherapy demonstrates long-term success in treating lymphoma   Mutations Point the Way to New Leukemia Drugs   At-home care of kids with leukemia prone to errors   Weill Cornell drug stops aggressive form of childhood leukemia   Dasatinib offers new options for leukemia patients   Drug combination shows promise for newly diagnosed blood cancer patients   Researchers Unlock Mystery of Very Aggressive Leukemia   Hodgkin’s survivors at increased risk for leukemia   A Collaboration to Find New Tools to Fight Leukemia   Smarter use of existing treatment helps dramatically boost survival of young AML patients   Anemia ups hospitalization, death risk for elderly   Formaldehyde raises risk of deadly cancers: study   Anemic Children with Cancer Benefit from Erythropoietin   Study reveals need for personalized approach in treatment of AML

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]